STOCK TITAN

Inovio: ADAR1 reports 7.4% beneficial ownership

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

INOVIO Pharmaceuticals, Inc. (INO) is the subject of a Schedule 13G reporting shared beneficial ownership by ADAR1 Capital Management, LLC and Daniel Schneeberger, ADAR1’s sole manager. Each reports 6,429,624 shares, or 7.4%, as of June 30, 2026. The reported amount comprises 2,143,910 common shares held directly by private funds managed by ADAR1 and its separately managed accounts, plus 4,285,714 shares underlying Tranche A and Tranche B warrants. The 7.4% figure is based on 82,341,945 INOVIO shares outstanding as of June 30, 2026.

Shared beneficial ownership 6,429,624 shares Reported by each reporting person as of June 30, 2026
Percentage of class 7.4% Based on shares outstanding as of June 30, 2026
Common shares held directly by managed funds and accounts 2,143,910 shares Included in the reported beneficial ownership
Shares underlying Tranche A and Tranche B warrants 4,285,714 shares Included in the reported beneficial ownership
Shares outstanding 82,341,945 shares As of June 30, 2026
beneficially owned regulatory
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared Voting Power regulatory
"Shared Voting Power 6,429,624.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Tranche A and Tranche B warrants financial
"4,285,714 shares of Common Stock underlying Tranche A and Tranche B warrants"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many INO shares does ADAR1 Capital Management report beneficially owning?

ADAR1 Capital Management, LLC and Daniel Schneeberger each report shared beneficial ownership of 6,429,624 shares, or 7.4%, as of June 30, 2026. The amount includes 2,143,910 common shares held by funds and separately managed accounts managed by ADAR1, plus 4,285,714 shares underlying Tranche A and Tranche B warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





45773H409

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent (i) 2,143,910 shares of common stock, par value $0.001 per share ("Common Stock"), of Inovio Pharmaceuticals, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1") and separately managed accounts of ADAR1 and (ii) 4,285,714 shares of Common Stock underlying Tranche A and Tranche B warrants held by private investment funds managed by ADAR1. Such securities may be deemed to be indirectly beneficially owned by ADAR1. The percentage in box 11 is based on 82,341,945 shares of Common Stock of Inovio Pharmaceuticals, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 12, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent (i) 2,143,910 shares of common stock, par value $0.001 per share ("Common Stock"), of Inovio Pharmaceuticals, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1") and separately managed accounts of ADAR1 and (ii) 4,285,714 shares of Common Stock underlying Tranche A and Tranche B warrants held by private investment funds managed by ADAR1. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. The percentage in box 11 is based on 82,341,945 shares of Common Stock of Inovio Pharmaceuticals, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 12, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026
Exhibit Information

Exhibit A: Joint Filing Agreement

Keep reading